Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $3 price target The firm views Ovid’s OV329 as a “differentiated” oral agent targeting a sub-population of the epilepsy therapy market. It believes this market is in a “dire need of new medicines.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics appoints Kaufmann as Chief Medical Officer
- Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright
- Leerink bullish on Ovid Therapeutics, initiates with an Outperform
- Ovid Therapeutics initiated with an Outperform at Leerink
- Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating